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must have at least 1 prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3), but no 
prior diabetes (ICD-9-CM: 250.xx) or bipolar disorder (ICD-9-CM: 296.4x–296.8x) 
diagnosis. The non-duloxetine patients were matched to the duloxetine patients 
via propensity scoring (1:1 ratio), controlling for differences in demographics, comor-
bidities, prior opioid use, and pain levels in the 12 months pre-index period. Paired 
t-tests were used to compare health care utilization over the 12 months post- 
index period including outpatient visits, emergency department (ED) visits, hospital 
admissions and length of hospital stay. Chi-square tests were used to compare 
percentages of patients with hospitalization or ED visit. RESULTS: The study 
sample included 878 patients (duloxetine: n  439; non-duloxetine: n  439) with 
comparable baseline characteristics. Compared with duloxetine patients, non-dulox-
etine patients on average had 12.0 more outpatient visits (95% Conﬁdence Interval 
[CI]: 6.4–17.5, p  0.0001), 0.16 more hospital admissions (CI: 0.07–0.26, p  0.001), 
and 0.79 more hospital days (CI: 0.17–1.41, p  0.013). Additionally, a higher per-
centage of non-duloxetine patients was hospitalized (17.8% vs. 10.9%, p  0.004). 
No group difference was found in ED visits. CONCLUSIONS: Controlling for cross-
cohort differences, VA patients who were treated with duloxetine were found to 
be associated with lower health care utilization than those treated with other 
antidepressants.
PMH30
A DYNAMIC MARKOV APPROACH ASSESSING THE BURDEN OF 
ILLNESS OF GENERALIZED ANXIETY (GAD) DISORDER IN CANADA
Bereza BG1, Machado M1, Papadimitropoulos M2, Sproule B3, Ravindran AV3, Einarson TR1
1University of Toronto, Toronto, ON, Canada, 2Eli Lilly & Company, Toronto, ON, Canada, 
3Centre for Addiction and Mental Health and University of Toronto, Toronto, ON, Canada
OBJECTIVES: GAD is a chronic disease with waxing and waning of symptoms; 
exerting substantial economic and humanistic impact. To date, economic evaluations 
have been limited to time horizons of 12 months. This study develops a dynamic 
decision model, quantifying the lifetime cost-of-illness (COI) for GAD (direct and 
indirect costs). METHODS: TreeAge® software was used to develop an incidence-
based Markov model with 9 health-states (6-month cycles): Family physician assess-
ment (initial), Specialist assessment for 2nd and 3rd line therapies, Maintenance 
therapies, Treatment discontinued and Death (absorbing). Patients seeking treatment 
enter the model between the ages of 18–80 and subject to age of onset. Pharmaco-
therapy based on Canadian Psychiatric Association (CPA) guidelines; revised and 
validated by an expert panel. Meta-analysis of CPA-cited evidence populated remis-
sion and response rates. Published literature determined absenteeism, treatment 
 discontinuation, onset of illness, and relapse rates. Physician, pharmacotherapy, hos-
pitalization costs based on published public (Province of Ontario) rates. All cause 
mortality (2000–2002) and hourly wage rates (2008) published by Statistics Canada. 
COI was reported in 2008 Canadian dollars, discounted at 5%. A total of 10,000 
iterations were used for 1st order micro-simulation. RESULTS: Mean lifetime COI/
patient  $6671(SD  $4678). Mean age of onset  48 years. Mean (SD) tracker values: 
Relapse/patient  1(1.02); Treatment resistant patients  20%(40%); Discontinued 
treatment time  13(8) years. Absorbing state (Death) captures 89% of patients. The 
range of uncertainty for relapse (1–5%) and cost of absenteeism ($0-$6,071) exerted 
the highest impact of all variables on mean COI $5,000–8,000 and $1,000–$12,000 
respectively. Breakdown cost analysis: 82% absenteeism, 8% pharmacotherapy, 7% 
physician, 2% hospitalization. 85% of all patients discontinued treatment by 4th year). 
CONCLUSIONS: This is the ﬁrst known study to model the course of GAD over a 
patient’s lifetime and quantify COI. Absenteeism contributes substantially to the COI 
for GAD. Relatively low attribution of pharmacotherapy cost to COI possibly due to 
treatment discontinuation.
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OBJECTIVES: To measure the total direct cost of depression and its distribution to 
different services using administrative databases from Alberta service providers. 
METHODS: We analyzed available administrative databases from Alberta Health and 
Wellness and the Alberta Mental Health Board from 2005–2006. The following cost 
information was obtained: psychiatric care, community mental health visits, regional 
inpatient and outpatient services, emergency room visits, and physician visits. Records 
were selected if the primary diagnosis for the service was depression disorder using 
2006 dollar values. Data was analyzed by age group. RESULTS: Depression in Alberta 
had a direct health care cost of $97 M in 2005–2006, representing 1.1% of the prov-
ince’s total health care costs. The treated prevalence of depression in 2005–2006 was 
estimated at 13%. The greatest cost driver was physician services ($42.6 M), followed 
by acute inpatient costs ($33.8 M). General practitioners incurred half of physician 
costs and treated nearly six times the number of individuals with depression than 
psychiatrists. Per capita cost to treat depression increases with age, with seniors rep-
resenting the highest cost per individual. Older adults tend to use and incur a greater 
cost in inpatient services, while outpatient or physician services are more heavily used 
by younger age groups. CONCLUSIONS: The estimated $97 M cost of depression in 
Alberta is likely to be an underestimation. We included individual data with a primary 
diagnosis of depression and could not include drug data or privately funded services. 
Our ﬁndings are consistent with previous research that people with depression are 
treated more frequently in primary care and that the cost to treat depression increases 
with age. Depression continues to be a heavy cost burden throughout Alberta and 
worldwide.
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OBJECTIVES: The main objective is to assess resource utilization and cost of schizo-
phrenia as well as cost drivers using a prospective cohort that followed a representative 
sample of 288 French patients. METHODS: This study is the ﬁrst comprehensive 
prospective study on cost of schizophrenia. Patients were randomly selected from three 
deﬁned catchment areas located in the North, Centre and South of France. Unit costs 
were based on the most valid available data, mainly health insurance and French 
public sources. Costs were deﬁned based on society perspective. Direct cost included 
treatment provided in inpatient services, intermediate facilities, outpatient visits and 
medication costs. Indirect costs were considered as productivity loss for unemployed 
or sick leave patients in working age. RESULTS: Average patient direct costs yield 
a3534, break down as 39.3% for inpatient treatment, 37.7% for day clinic, and 
16.1% for medication. The remaining includes visits to psychiatrists, GP’s, psycholo-
gists and other physicians. Assuming 1% prevalence of schizophrenia, the estimation 
of annual direct costs yields a1, 581, 111, 600, and indirect cost of schizophrenia 
linked to productivity loss in France yields a2, 214, 488, 006. Several cost drivers 
were identiﬁed: relapse during the follow-up period, positive symptoms of schizophre-
nia, and depressive symptoms at baseline predict higher costs, while satisfaction with 
their health or negative symptoms of schizophrenia at baseline was linked with lower 
costs. CONCLUSIONS: This study highlights the heavy societal burden of schizophre-
nia in France, of which hospitalization (day and full time) services account for 77%. 
Any attempt to anticipate and prevent hospitalization might have signiﬁcant effect on 
the cost of schizophrenia. Such intervention is likely to be cost effective.
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OBJECTIVES: Bipolar disorder (BD) is a long-term condition that has a high impact 
on patients, families, health care systems and society. One of the main challenges in 
mental health is to determine the burden associated with it. The purpose is to establish 
the different perspectives and measures used to asses the burden of BD. METHODS: 
A systematic review was performed to identify studies in PUBMED, MEDLINE, 
EMBASE and Cochrane library. The search strategy used the MeSH terms: “bipolar 
disorder” & “cost of illness”, combined with “burden of disease”, “disease burden” 
& “burden of illness”. There weren’t constrains on date or language. Titles and 
abstracts were examined by reviewers, selecting for inclusion articles reporting an 
explicit aim to evaluate the burden of BD, measured by prevalence, morbidities associ-
ated, lost of quality of life, disabilities, impairments and/or costs. Articles were classi-
ﬁed into 4 categories, depending on focus studied: 1) patients; 2) caregivers (family, 
partners); 3) health care-system; and 4) society. RESULTS: A total of 188 articles were 
identiﬁed, 32 met study criteria. Eleven studies were reviews, and 21 were manuscripts, 
classiﬁed as 53.1% caregivers (n  17), 28.2% health care-system (n  10), 15.6% 
patients (n  5) and 3.1% society (n  1). The main outcome measures were: distress 
and subjective burden in caregivers scope, costs in health care-system, morbidity in 
patients and a set of all (prevalence, patient-related issued, disabilities and costs) in 
society. CONCLUSIONS: Concept of burden of disease varies depending on the 
studies perspectives and researchers concern. Our study suggests that the main interest 
when evaluating the burden of BD is focused on assessing the impact of the disease 
on relatives. As BD causes a high level of impairments and disabilities, that affects 
specially to caregivers, costs associated with it are difﬁcult to estimate. Additional 
research is needed in order to determine them properly.
PMH34
COSTS OF SCHIZOPHRENIA WITHIN A LARGE GERMAN STATUTORY 
HEALTH INSURANCE FUND
Zeidler J1, Mittendorf T2, Greiner W3
1Leibniz University of Hannover, Hannover, Germany, 2Herescon gmbh, Hannover, 
Germany, 3University of Bielefeld, Bielefeld, Germany
OBJECTIVES: Data concerning costs of illness in patients with schizophrenia are          
scarce in Germany. Aim of this claims data analysis was to examine the costs of 
schizophrenia from the perspective of a major statutory health insurance fund. 
METHODS: A nation-wide database was used to evaluate the costs of schizophrenia           
in 2006. All patients with schizophrenia (ICD F20) were identiﬁed via a special algo-
rithm based on claims data. All schizophrenia related costs for outpatient care, inpa-
tient care, medications, rehabilitation, occupational therapy, and sick leave payments 
were analysed. RESULTS: Data from 11,513 patients were available, with 47%        
being female (and 46 years of age). Mean costs of EUR 4,966 in the year 2006 were 
incurred from the health insurance perspective. A total of a2924 (59 %) were incurred 
by inpatient care, and a1333 (27 %) were due to medication. A total of a421 (8 %) 
resulted from schizophrenia related outpatient psychological specialists visits. Costs 
